Validation of Immune‐Related Adverse Event (<scp>irAE</scp>) Case Definitions in a Real‐World Lung Cancer Population

In this validation study of five irAE case definition algorithms, a combination of ICD-10 codes and medication administration codes generally perform well to identify more severe irAE (CTCAE Grade 3-5), and severe pneumonitis, hepatitis, and colitis (common irAEs) among all possible irAE severity levels and sites. Medication codes alone perform well at identifying severe irAE, while the most stringent algorithm (mirroring guideline-recommended irAE treatment) has the highest Sp and PPV. Algorithms have utility for comparing the relative risk of irAE between regimens or patient subgroups.

Authors

Institutions

Publication Details

Journal
Pharmacoepidemiology and Drug Safety
Published
2025-02-01
DOI
https://doi.org/10.1002/pds.70100
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Validation of Immune‐Related Adverse Event (irAE) Case Definitions in a Real‐World Lung Cancer Population

Jodi B Segal, Hemalkumar B. Mehta, Joseph C. Murray, James Heyward
1 citations
Pharmacoepidemiology and Drug Safety
Cancer Immunotherapy and Biomarkers
1.05
article

Validation of Immune‐Related Adverse Event (irAE) Case Definitions in a Real‐World Lung Cancer Population

Jodi B Segal, Hemalkumar B. Mehta, Joseph C. Murray, James Heyward
article en
1 citations

Abstract

In this validation study of five irAE case definition algorithms, a combination of ICD-10 codes and medication administration codes generally perform well to identify more severe irAE (CTCAE Grade 3-5), and severe pneumonitis, hepatitis, and colitis (common irAEs) among all possible irAE severity levels and sites. Medication codes alone perform well at identifying severe irAE, while the most stringent algorithm (mirroring guideline-recommended irAE treatment) has the highest Sp and PPV. Algorithms have utility for comparing the relative risk of irAE between regimens or patient subgroups.

Pharmacoepidemiology and Drug SafetyVol. 34(2)
Johns Hopkins University (US), Sidney Kimmel Comprehensive Cancer Center (US)
Johns Hopkins University, Centers for Disease Control and Prevention, National Institute on Aging, National Heart, Lung, and Blood Institute, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 25%
Cancer Immunotherapy and Biomarkers
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.